Sutro Biopharma

Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma headquartered in United States, North America, operates in the Information Technology, Biotechnology, Medical sector. The company focuses on Information Technology and has secured $91.7B in funding across 144 round(s). With a team of 251-500 employees, Sutro Biopharma is actively contributing to advancements in Information Technology. Their latest funding round, Series B - Sutro Biopharma, raised $15.0M. Discover more about their projects, partnerships, and impact on our platform.